Company intelligence / Profile preview

Amai Proteins

Rehovot, Central District / Rehovot area, Israelamaiproteins.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Amai Proteins has developed Sweelin®, a hyper-sweet protein that can reduce added sugars by up to 70% in various foods and beverages. The company has successfully completed the world’s first human clinical trial demonstrating the safety and effectiveness of its sweet proteins as a sugar substitute. Their technology enables large-scale, cost-effective production with high stability, shelf life, and heat resistance.

Therapeutic areas: Metabolic Disorders
Modalities: ProteinRecombinant protein
Industry: Non-Drug Biotech

Drug pipeline

1 asset

sweelin

Commercial

Indications: Sugar reduction

Partnerships

EIT FoodThe Kitchen FoodTech HubIsrael Innovation Authority

Beyond the preview

Go deeper on Amai Proteins.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amai Proteins.

Explore the full profile